XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
US Stock MarketDetailed Quotes
ACTU Actuate Therapeutics
- 7.760
- +0.030+0.39%
Close Feb 14 16:00 ET
151.57MMarket Cap-5.33P/E (TTM)
7.892High7.130Low51.98KVolume7.660Open7.730Pre Close389.25KTurnover1.86%Turnover RatioLossP/E (Static)19.53MShares11.73052wk High28.32P/B21.73MFloat Cap5.51052wk Low--Dividend TTM2.80MShs Float11.730Historical High--Div YieldTTM9.85%Amplitude5.510Historical Low7.488Avg Price1Lot Size
Trending Stocks
Discussing
Many institutions are bullish! What's ahead for Chinese stocks in 2025?
Recently, institutions such as Goldman Sachs, Morgan Stanley, and Appaloosa LP have spoken positively about Chinese assets. 🎙️Discussion: 1
Popular on moomoo
Feb 13 17:34
China's asset revaluation sparks debate: What are mooers buying?
Actuate Therapeutics Stock Forum
Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer
Tuesday, 7th January at 8:00 am
CHICAGO and FORT WORTH, Texas, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen...
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits
5. Always remember shorts include dark pools.
6. Most importantly, don’t blame for your losses. I already give watchlist and stock education. The ball is on you.
$KULR Technology (KULR.US)$ PR 12/17: Signs Service Agreement to Launch KULR ONE Space Battery. COH $13.4M good for 9 months✅
$Wearable Devices (WLDS.US)$ PR 12/17:...
Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer
Tuesday, 17th December at 8:00 am
• Statistical Significance Met on Primary Endpoints of 1 Year Survival Rate and Median Overall Survival
• Doubling of 1 Year Survival Rate and 37% Reduction in Risk of Death
• Two Month (29%) Increase in Median Overall Survival
• Multiple Patients with Complete Responses (CRs) and/or Partial Re...
CHICAGO and FORT WORTH, Texas, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), announced that it will participate in “Webinar Wednesday” hosted b...
No comment yet